Drug Delivery and Nanotechnology Module

药物输送和纳米技术模块

• 批准号: 9795551
• 负责人: Kannan Rangaramanujam
• 金额: $ 8.19万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9795551
• 关键词: Collaborations; Core Grant; Development; Disease; Doctor of Philosophy; Drug Delivery Systems; Eye; Faculty; Glaucoma; Grant; Institutes; Legal patent; Nanotechnology; Nucleic Acids; Optic Nerve Injuries; Proteins; Publications; Research Personnel; Resources; Retinopathy of Prematurity; System; Technology; Therapeutic; United States National Institutes of Health; Universities; Vision research; base; clinical translation; eye dryness; imaging approach; innovation; nanomedicine; novel diagnostics; novel imaging technology; novel therapeutic intervention; novel therapeutics; off-patent; ranpirnase; small molecule; targeted delivery; tool; vision science

PROJECT SUMMARY – NANOTECHNOLOGY The Drug Delivery and Nanotechnology (DD&N) module is an enabling technology resource available to faculty of the Wilmer Eye Institute, by enabling sustained and targeted delivery of drugs administered intravitreally, subconjunctivally, or systemically, and in developing novel imaging technologies. During the current period, the collaborations have resulted many NIH grants, publications, many patents licensed, and significant translational efforts, with multiple therapeutic approaches developed by the Wilmer P30 team undergoing clinical translation. DD&N takes advantage of the expertise, technologies, and resources of the Wilmer Eye Institute’s Center for Nanomedicine (CNM). The Center for Nanomedicine at Wilmer serves as an anchor for the DD&N module, and has grown to seven faculty, collaborating with more than 15 faculty in Wilmer and more than 100 faculty across Johns Hopkins. Demand by Wilmer investigators (both established and early investigators) for the development and characterization of drug delivery systems for small molecules, proteins, and nucleic acids have grown well beyond the available budgetary restrictions of the CNM, with the DD&N becoming an integral part of the P30 effort. Our collaborative efforts have led to significant progress in novel therapeutic approaches for the treatment of glaucoma, optic nerve injury, retinopathy of prematurity, and dry eye. The DD&N module will continue to thrive and enable significant discoveries by the P30 collaborators.

项目摘要 - 纳米技术 药物输送和纳米技术（DD＆N）模块是可用的技术资源 通过实现毒品的持续和有针对性的毒品，向威尔默眼科研究所的教师 在开发新型成像时进行玻璃体内，副结合或系统地施用 技术。 出版物，许多专利获得许可和重大翻译工作，并具有多种治疗性 Wilmer P30团队正在开发临床翻译。 威尔默眼协会中心的专业知识，技术和资源的优势 纳米医学（CNM）。 模块，已经成长为七个教职员工，与威尔默的15多名教师合作等等 约翰·霍普金斯（Johns Hopkins）的100名教职员工。 研究人员）针对小分子的药物输送系统的开发和表征， 蛋白质和核酸已远远超出了CNM的可用预算限制， 随着DD＆N成为P30的组成部分。 新型治疗方法治疗Glavaucoma，视神经损伤， 预防性的视网膜病和干眼。 P30合作者的重大发现。